(INMB) INmune Bio, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(INMB) INmune Bio, Inc. Complete Analysis Pack
INmune Bio: A Clear Business Model Canvas for Investors
Discover how INmune Bio, Inc. turns breakthrough immunology into a focused business strategy. This full Business Model Canvas maps its value proposition, key partners, revenue logic, and growth levers in one clear view. Perfect for investors, analysts, and founders who want the complete strategic picture—before making their next move.
Partnerships
Xencor licensing agreement
INmune Bio, Inc. uses its licensing relationship with Xencor, Inc. to access external immune-oncology technology, which helps it add pipeline assets without building everything in-house. That kind of licensing can cut discovery risk and speed development, especially for a small biotech with limited internal R&D scale.
Immune Ventures, LLC licensing agreement
Immune Ventures, LLC is one of INmune Bio, Inc.’s licensing partners, giving the company access to asset rights or know-how that can support its proprietary immunotherapy pipeline. In INmune Bio, Inc.’s latest public filings, the company continued to fund R&D with no product revenue reported, so these licensing ties remain important for advancing programs without building every asset in-house.
University of Pittsburgh collaboration
The University of Pittsburgh is one named institutional partner in INmune Bio, Inc.’s model, and that kind of academic tie helps move lab findings into translational research and scientific validation. It can also support publication and clinical development, which matters for a company with 1 institutional collaboration highlighted here.
Academic partners like the University of Pittsburgh can add peer review, trial know-how, and credibility without the cost of building all that in-house.
University College London collaboration
University College London gives INmune Bio access to deep disease biology and translational expertise, which is useful for early science, mechanistic work, and clinical insight. UCL is a top-tier research university with about 51,000 students and more than 18,000 staff, so the partnership can speed target validation and study design.
- Supports mechanistic biology
- Adds clinical disease insight
- Strengthens early-stage research
Clinical sites and CRO partners
INmune Bio, Inc. relies on clinical sites and CROs to run its multi-site trials, especially for patient screening, enrollment, safety checks, and data capture. In 2025, this kind of outsourced trial network was still key for a clinical-stage biotech because it speeds execution and keeps study operations lean.
- Supports multi-site enrollment
- Handles monitoring and data collection
- Lets INmune Bio scale trials faster
INmune Bio’s Partner Network Powers Its Pipeline
INmune Bio, Inc. depends on external partners to extend its science and keep costs lean: Xencor, Inc. and Immune Ventures, LLC for licensed tech, University of Pittsburgh and University College London for translational research, and CROs plus trial sites for clinical execution. These ties help INmune Bio, Inc. add assets, validate biology, and run multi-site studies without building every function in-house.
| Partner | Role |
|---|---|
| Xencor, Inc. | Licensing |
| UCL | Research |
| CROs/sites | Trials |
What is included in the product
Detailed Word Document
A concise Business Model Canvas capturing INmune Bio, Inc.’s immunotherapy strategy, key stakeholders, and value creation across the 9 core blocks.
Customizable Excel Spreadsheet
Quickly map INmune Bio’s business model to spot gaps, align teams, and streamline strategy decisions.
Reference Sources
Provides a credible source trail for INmune Bio, Inc., helping investors verify key claims fast and make better decisions with less uncertainty.
Activities
INKmune clinical development
INKmune clinical development is a core oncology activity for INmune Bio, Inc., spanning two lead indications: relapsed or refractory ovarian carcinoma and high-risk myelodysplastic syndrome. The work centers on trial design, patient enrollment, and outcome analysis, with each program needing clear endpoints and safety data to move toward late-stage readouts.
INB03 oncology development
INmune Bio, Inc. is advancing INB03 in hematologic malignancies and solid tumors through dose selection, biomarker testing, and early clinical readouts. As of 2026, the program has no disclosed product revenue, so the key activity is still pipeline expansion across cancer types, not commercial execution.
XPro1595 Alzheimer’s development
XPro1595’s Alzheimer’s program pushes INmune Bio beyond oncology into chronic inflammatory and neurodegenerative disease, so it needs neurology-specific trial design, biomarker work, and proof of cognitive benefit. That matters in a large market: about 6.9 million Americans age 65+ live with Alzheimer’s, and the disease already drives high, long-duration R&D and care costs.
Translational biomarker research
Translational biomarker research is central for INmune Bio, Inc. because its innate-immune programs need clear response signals and mechanism-of-action readouts to prove biologic effect. These biomarker studies help select the right patients and make Phase 1/2 trial data easier to read, especially when endpoints are still early and small-sample.
- Tracks response signals
- Shows mechanism-of-action
- Supports patient selection
- Improves trial interpretation
Regulatory and CMC execution
INmune Bio, Inc. must execute regulatory filings plus CMC (chemistry, manufacturing, and controls) to keep clinical supply GMP-ready. This work protects safety, batch consistency, and trial start dates, and it is central to moving assets through FDA review and into patient dosing.
- File and maintain regulatory packages
- Control clinical-grade manufacturing
- Keep supply ready for trials
- Support safety and lot consistency
INmune Bio Advances Phase 1/2 Pipeline with No Product Revenue Yet
INmune Bio, Inc.'s key activities are clinical development, biomarker validation, and regulatory/CMC work for INKmune, INB03, and XPro1595. In 2025/2026, the focus stayed on Phase 1/2 execution, since INmune Bio, Inc. still had no disclosed product revenue and Alzheimer's affects about 6.9 million Americans age 65+.
| Activity | 2025/2026 signal |
|---|---|
| Clinical trials | Phase 1/2 |
| Biomarkers | Response readouts |
| CMC/regulatory | GMP supply ready |
What You See Is What You Get
Business Model Canvas
The INmune Bio, Inc. Business Model Canvas preview you’re viewing is the exact document you’ll receive after purchase. It’s not a sample or mockup—this is a live snapshot from the final file, formatted the same way. Once you complete your order, you’ll get full access to this same ready-to-use document.
Resources
Licensed IP portfolio
INmune Bio, Inc.’s licensed IP portfolio is a core intangible asset that protects its therapeutic candidates and supports exclusivity. In 2025, that moat mattered because the company still had no product revenue, so licensed rights were central to value creation and to defending lead programs like XPro and INKmune.
Three named pipeline programs
INKmune, INB03, and XPro1595 are INmune Bio, Inc.’s three core pipeline assets, spanning oncology and neurology. They are the main value drivers, with XPro1595 already in late-stage clinical work and the two oncology programs shaping the company’s longer-term growth.
Innate immune system platform
INmune Bio’s key resource is its innate immune system platform, the core of its drug development model. It targets immune dysfunction at the source, which sets Company Name apart from conventional targeted drug developers focused on single pathways.
Clinical-stage expertise
INmune Bio, Inc., founded in 2015, is a clinical-stage biotech, so clinical development expertise is a core resource. This know-how helps the Company design and run trials, move assets through the clinic, and support future partnering as it advances programs like XPro1595 and CORDstrom.
- Founded in 2015
- Clinical-stage biotech
- Supports trial design and execution
- Helps drive partnering
Boca Raton headquarters
INmune Bio, Inc. is headquartered in Boca Raton, Florida, giving the company 1 core corporate hub for management, administration, and program oversight. This site is a key governance resource that keeps R&D, finance, and operating decisions aligned from a single base.
- 1 Boca Raton headquarters
- Centralizes oversight and coordination
- Supports management and administration
INmune Bio’s Core Assets Power Its Late-Stage Pipeline
INmune Bio, Inc.’s key resources are its licensed IP, innate immune platform, and late-stage pipeline led by XPro1595, INKmune, and INB03. The company’s 1 Boca Raton headquarters and in-house clinical development know-how support trial design, execution, and partnering.
| Resource | Role |
|---|---|
| Licensed IP | Protects lead programs |
| Innate immune platform | Drives drug discovery |
| XPro1595, INKmune, INB03 | Main value drivers |
| Boca Raton HQ | Central oversight |
Value Propositions
Novel innate immune therapy
INmune Bio develops novel innate immune therapies that aim to reset immune signaling rather than broadly suppress it, giving the Company a more differentiated immunotherapy angle. This approach targets multiple diseases through the same biology, which can expand use cases and improve the odds of better outcomes.
Oncology pipeline breadth
INmune Bio, Inc. spreads its oncology bet across 4 target areas: ovarian carcinoma, myelodysplastic syndrome, hematologic malignancies, and solid tumors. That breadth gives exposure to several high-unmet-need cancer markets and can lower dependence on any one indication if a single program slips.
Neurodegeneration program
XPro1595 extends INmune Bio, Inc. into Alzheimer’s disease, a market with about 55 million people worldwide and U.S. care costs above $350 billion a year. It adds a non-oncology growth path in a large unmet need with clear commercial upside.
Precision clinical positioning
INKmune is positioned for relapsed or refractory ovarian carcinoma and high-risk MDS, where options are thin: high-risk MDS carries a median overall survival of about 9 to 12 months, and platinum-resistant ovarian cancer has a 5-year survival near 31%. That focus can sharpen clinical differentiation and support a clear value story in hard-to-treat, high-need settings.
- Targets late-line, high-unmet-need patients
- Built for clinical differentiation
- Supports focused trial and commercial positioning
Licensed science foundation
INmune Bio, Inc. builds its Value Proposition on licensed science and academic links, which can move programs faster and cut early discovery spend. In 2025/2026, that matters because the company is still precommercial, so external IP and research partners help support scientific credibility while limiting internal R&D burden.
- Licensed IP lowers early discovery costs
- Academic ties speed validation
- External science adds credibility
INmune Bio Targets Two Big Unmet-Need Markets
INmune Bio, Inc. offers a differentiated innate-immune reset platform aimed at late-line cancers and Alzheimer’s disease, with XPro1595 in AD and INKmune in ovarian carcinoma and high-risk MDS. That mix targets high-unmet-need settings where survival is poor and treatment choices are thin.
| Program | Need | Value |
|---|---|---|
| XPro1595 | 55M Alzheimer’s cases | Large non-oncology upside |
| INKmune | HR-MDS OS 9-12 months | Focused late-line edge |
Customer Relationships
Clinical trial participant management
Patients in INmune Bio studies need close monitoring, and the company works through investigators and trial teams, not direct patient contact. This setup helps protect safety, keep participants in study, and improve data quality in a clinical-stage business with no product revenue yet.
Physician and investigator engagement
In 2025, INmune Bio kept oncologists, hematologists, and neurologists close because they are the core scientific users for its programs. Ongoing input from these specialists helps shape trial design, support enrollment, and speed clinical adoption.
Academic collaboration model
INmune Bio, Inc. uses an academic collaboration model built on long-term ties with universities and research institutes, where joint studies help validate its science and broaden the evidence base. These partnerships deepen the company’s scientific network and support future clinical and translational research, which is key for a platform-focused biotech.
Partner-oriented business development
INmune Bio’s partner-oriented business development depends on tight, milestone-based communication across its 3 clinical programs, so collaborators get data, safety updates, and trial progress fast. That keeps licensing talks moving and can support higher deal value as assets advance from early clinical work toward later-stage readouts.
- 3 clinical programs
- Milestone updates protect deal value
- Shared data speeds partner decisions
Investor and stakeholder reporting
INmune Bio, Inc. uses investor reporting as a core trust tool: it shares SEC filings, quarterly financial updates, and clinical readouts on pipeline progress so shareholders can track trial data, cash use, and milestones. For a public biotech, that steady disclosure helps support capital access and keeps market expectations aligned with execution.
- Regular SEC and earnings updates
- Clinical data and pipeline milestones
- Transparency supports funding access
INmune Bio’s Investigator-Led Model Drives 3 Clinical Programs
INmune Bio’s customer relationships are mainly investigator-led and partner-led, with oncologists, hematologists, neurologists, and academic collaborators shaping trial design, enrollment, and translational work. In 2025, this model supported 3 clinical programs and kept data, safety, and milestone updates flowing to trial sites, partners, and investors.
| Focus | 2025 data |
|---|---|
| Clinical programs | 3 |
| Core users | Oncologists, hematologists, neurologists |
Channels
Clinical trial sites
Patients access INmune Bio, Inc.’s therapies through clinical trial sites, which are the main channel for its development-stage assets and handle screening, dosing, and follow-up. In INmune Bio, Inc.’s 2025 10-K, the company still had no product revenue, so these sites remain the only direct route to patients.
Academic medical centers
Academic medical centers are core referral and research channels for INmune Bio, Inc., especially for complex oncology and neurology studies that need expert investigators, imaging, and biomarker work. U.S. academic sites sit near the NIH's $48.6 billion FY2024 research engine, so they also raise scientific credibility and help speed KOL adoption.
Licensing and partnership networks
External partners help INmune Bio move science from academia into clinical programs by sharing know-how, assets, and trial access, then support future commercialization through licensing. This matters because INmune Bio reported $53.8 million in cash, cash equivalents, and marketable securities at 2025 year-end, so partner-led development can extend runway without heavy upfront spend.
Scientific conferences
INmune Bio, Inc. can use oncology, neurology, and immunology conferences to share clinical data with physicians, researchers, and investors. These meetings drive awareness and credibility, and major scientific congresses often draw thousands of specialists, giving one presentation broad reach.
- Reaches key medical opinion leaders
- Supports investor visibility
- Builds trust through peer review
SEC filings and investor relations
INmune Bio, Inc. uses SEC filings and investor relations to reach capital markets with pipeline, risk, and cash updates. As a clinical-stage company with no commercial product revenue, these disclosures are central to funding trials and explaining progress, dilution, and going-concern risk.
Latest filings and releases keep investors current on trial readouts, R&D spend, and liquidity, which directly shape valuation.
- Shows pipeline progress and trial data
- Discloses cash, burn, and dilution risk
- Supports access to equity capital
INmune Bio Relies on Clinical and Capital Channels
INmune Bio, Inc.’s main channels are trial sites, academic centers, conferences, and SEC/IR updates, because it had no product revenue in 2025 and still depends on clinical access and capital-market reach. Partnered development also matters, since year-end 2025 cash, cash equivalents, and marketable securities were $53.8 million.
| Channel | Use |
|---|---|
| Trial sites | Patient access |
| IR/SEC | Fundraising |
Customer Segments
Relapsed ovarian carcinoma patients
INKmune targets women with relapsed or refractory ovarian carcinoma, a core oncology group where most advanced patients eventually recur after platinum-based therapy and have few durable options. Ovarian cancer still causes about 200,000 deaths worldwide each year, and platinum-resistant relapse remains one of the highest unmet-need settings in gynecologic oncology.
High-risk MDS patients
High-risk myelodysplastic syndrome patients are a key INKmune target because this segment has fast progression and poor survival; high/very-high risk MDS often carries median overall survival near 1-2 years and can progress to acute myeloid leukemia in up to 30% of cases. That makes it a clinically urgent hematology niche with clear unmet need.
Hematologic malignancy and solid tumor patients
INB03 targets hematologic malignancies and solid tumors, tapping into a broad cancer market; GLOBOCAN 2022 estimated 20.0 million new cancer cases and 9.7 million deaths worldwide. That wider reach expands the treated population and reduces reliance on any single indication, strengthening INmune Bio, Inc.'s clinical portfolio.
Alzheimer’s disease patients
Alzheimer’s disease patients are a large neurology segment for INmune Bio, Inc.: about 7.2 million Americans age 65+ live with Alzheimer’s disease in 2025, and global dementia cases are about 55 million. XPro1595 is being developed for this chronic brain disease, so the addressable pool is broad and recurring.
- About 7.2 million U.S. patients
- About 55 million dementia cases worldwide
- XPro1595 targets a chronic neurology need
Hospitals and specialist physicians
Hospitals and specialty centers are INmune Bio, Inc.’s main operating customer base, because oncologists, hematologists, and neurologists drive referral flow, trial enrollment, and later adoption. This matters most in complex areas like oncology, blood disorders, and neuroinflammation, where treatment decisions depend on specialist trust and site capabilities.
- Specialists influence trial uptake.
- Hospitals run clinical execution.
- Centers enable future use.
INmune Bio Targets Big-Need Patient Niches
INmune Bio, Inc. serves narrow, high-unmet-need patient groups: women with relapsed or refractory ovarian carcinoma, high-risk MDS patients, and people with Alzheimer’s disease. Its trials also depend on hospitals and specialty centers, because these sites drive referral, enrollment, and future use.
| Segment | Key data |
|---|---|
| Ovarian cancer | ~200,000 deaths/year |
| Dementia | ~55 million cases worldwide |
| U.S. Alzheimer’s | ~7.2 million age 65+ |
Cost Structure
Clinical trial expenses
Clinical trial expenses are INmune Bio, Inc.'s biggest cost driver, covering patient recruitment, site payments, monitoring, and data management. In biotech, Phase 3 programs can cost tens of millions of dollars, and clinical development often takes the largest share of R&D spend, so costs usually rise as trials move from early to late stage.
Research and discovery spend
Research and discovery spend is the core cost driver for INmune Bio, Inc., because lab work, biomarker analysis, and preclinical studies must stay funded to advance innate-immune assets. In its latest filings, R&D remained the main operating expense, reflecting the need to support both new and existing programs through continuous scientific testing.
Manufacturing and CMC costs
Manufacturing and CMC costs cover clinical supply runs, GMP quality testing, and process development, and they are a fixed burden in biologics because every trial batch must meet release specs before dosing. For INmune Bio, Inc., this spend is tied to keeping investigational material usable in studies, so delays or rework can push cash use higher fast.
General and administrative costs
INmune Bio, Inc.'s general and administrative costs are the public-company overhead layer: salaries, legal, accounting, audit, and investor relations. These non-lab expenses fund governance and SEC reporting, and in a small biotech they often sit alongside R&D as a material cash use while not advancing the lab pipeline directly.
- Public-company salaries and benefits
- Legal, audit, and accounting fees
- Investor relations and compliance
- Non-laboratory overhead spend
IP and licensing costs
INmune Bio, Inc. treats IP and licensing as a recurring cash drain: upfront fees, milestone payments, and patent/legal defense all sit in this cost line. In 2025, the company reported $0 in product revenue and continued to fund R&D and IP protection from cash on hand, so even modest license or filing costs can matter.
- Upfront license fees
- Milestone-based payments
- Patent and legal costs
- Ongoing rights protection
INmune Bio Burns Cash on R&D as Product Revenue Stays at Zero
INmune Bio, Inc. cost structure is still dominated by R&D, especially clinical trials, lab work, CMC, and IP protection. In 2025, the company reported $0 product revenue, so these costs were funded mainly from cash and capital raises, not sales.
| Cost item | 2025 signal |
|---|---|
| Clinical trials | Largest spend |
| R&D and CMC | Core cash use |
| G&A and IP | Fixed overhead |
Revenue Streams
Licensing income
Licensing income lets INmune Bio, Inc. monetize its patents and know-how before product launch through upfront fees, milestone payments, and royalties. This is common in clinical-stage biotech, where product revenue is often still 0 and IP deals can fund R&D while trials run.
For INmune Bio, Inc., the value is in turning a 2025 research asset into cash without waiting for commercialization, with economics often tied to FDA or partner milestones worth millions per deal. In 2026, this stream can sit alongside financing as a key non-dilutive funding source.
Collaboration milestone payments
INmune Bio, Inc. had 0 collaboration revenue in 2025, so milestone cash is still event-driven, not recurring. Development payments can land only when partner targets are hit, which helps fund clinical advancement without steady sales.
Grant funding
Grant funding can bring INmune Bio non-dilutive cash for academic and disease-focused work, which helps fund early science and translational studies without issuing shares. For high-risk biotech programs, even one awarded grant can offset part of multi-year R&D spend and keep optionality alive while the company advances its pipeline.
Equity financing
INmune Bio, Inc. relies on equity financing as a core revenue stream because it is still a development-stage biotech company. These capital raises fund R and D, clinical trials, and day-to-day operations, and they usually matter most before any product sales begin.
- Funds research and trials
- Covers operating cash needs
- Supports pre-commercial growth
Future product sales and royalties
INmune Bio, Inc. has no approved products yet, so this revenue stream is still future-facing. If a candidate wins approval, sales would become a direct top-line source, while partnered programs could also bring royalties from commercialization.
- Direct sales start after approval
- Royalties can follow partner launches
- Still the main long-term monetization path
INmune Bio Still Relies on Equity, Not Revenue, to Fund Operations
INmune Bio, Inc. revenue is still driven by non-product sources: in 2025 it reported 0 collaboration revenue and no approved-product sales. The main cash flow remains equity financing, with licensing, grants, and future milestones as secondary, event-driven inflows.
| Stream | 2025 |
|---|---|
| Collaboration revenue | 0 |
| Product sales | 0 |
| Main funding source | Equity |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.